Markus Höltje
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Markus Höltje has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
Ingo Just
Department of Neurology, Focus Program Translational Neuroscience and Immunotherapy, Rhine-Main Neuroscience Network, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
9 shared publicationsGudrun Ahnert‐Hilger
Laboratory of Neurobiology, Max‐Planck‐Institute for Biophysical Chemistry and University of Göttingen Göttingen Germany
7 shared publicationsGudrun Ahnert-Hilger
Department of Neurology, Focus Program Translational Neuroscience and Immunotherapy, Rhine-Main Neuroscience Network, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
6 shared publicationsAstrid Rohrbeck
Department of Neurology, Focus Program Translational Neuroscience and Immunotherapy, Rhine-Main Neuroscience Network, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
4 shared publicationsFred Hofmann
Institute of Toxicology, Hannover Medical School (MHH), Carl-Neuberg-Straße 1, D-30625 Hannover, Germany
4 shared publications- Francesco Boato
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA
3 shared publications
Latest Publications
- Open Access
- 27 July 2026
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 23 (1) , 258
Copine-5-IgG-related autoimmune encephalitis: a novel paraneoplastic neurological syndrome with a strong melanoma association
Background: Although significant progress has been made in identifying antigen targets in autoimmune encephalitis (AIE), in a substantial proportion of patients with presumed AIE no known autoantibodies can be detected. Herein, we describe a novel autoantibody reactivity, directed against copine-5 (CPNE5), in patients with AIE and melanoma. Methods: Patients were identified through routine clinical testing for anti-neural autoantibodies by indirect immunofluorescence on neuronal tissue sections. The antigen was identified by immunoprecipitation and mass spectrometry and confirmed by recombinant protein assays. Results: Serum and cerebrospinal fluid (CSF) immunoglobulin G (IgG) from four patients was found to exhibit distinct binding to cerebellar and hippocampal neurons. Copine-5 was identified as the target antigen. Clinical manifestations included cognitive decline, confusion/disorientation, psychosis, seizures and signs and symptoms compatible with basal ganglia involvement (movement disorders, including secondary parkinsonism, and/or abulia/akinetic mutism), alongside pain (including painful tonic spasms and focal allodynia), dysarthria, dysphagia, and abducens nerve palsy. Brain magnetic resonance imaging disclosed hyperintense lesions in the basal ganglia and the temporal lobe. CSF analysis revealed mild pleocytosis, intrathecal IgG synthesis, and blood/CSF barrier dysfunction. Of particular note, all four patients had melanoma, with an occult primary in three. In one patient, melanoma diagnosis and immunotherapy with the anti-PD-1 immune checkpoint inhibitor nivolumab preceded the onset of AIE by 9 months. Glucocorticoid treatment and/or intravenous immunoglobulins led to transient improvement in at least three patients; however, all relapsed and three progressed to hypoactive delirium or mutism. Plasma exchange and cyclophosphamide treatment were followed by clinical improvement and stabilization in one patient, but potentially contributed to fatal infectious complications. Copine-5-IgG belonged to the strongly complement-activating IgG1 subclass and was produced intrathecally. Serum titers ranged between 1:1000 and 1:100,000. Conclusions: Copine-5 is a novel autoantibody target in AIE. Testing for anti-copine-5 autoantibodies should be included in the diagnostic workup of patients with AIE, especially, but not exclusively, if associated with melanoma or positive melanoma-associated tumor markers. Further studies investigating the immunopathogenesis of copine-5-related autoimmunity and the potential significance of anti-copine-5 as a novel paraneoplastic serological marker and of copine-5 as a histopathological tumor marker in patients with suspected melanoma are highly warranted.
- 27 July 2026
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 23 (1) , 258
Open AccessCopine-5-IgG-related autoimmune encephalitis: a novel paraneoplastic neurological syndrome with a strong melanoma association
Background: Although significant progress has been made in identifying antigen targets in autoimmune encephalitis (AIE), in a substantial proportion of patients with presumed AIE no known autoantibodies can be detected. Herein, we describe a novel autoantibody reactivity, directed against copine-5 (CPNE5), in patients with AIE and melanoma. Methods: Patients were identified through routine clinical testing for anti-neural autoantibodies by indirect immunofluorescence on neuronal tissue sections. The antigen was identified by immunoprecipitation and mass spectrometry and confirmed by recombinant protein assays. Results: Serum and cerebrospinal fluid (CSF) immunoglobulin G (IgG) from four patients was found to exhibit distinct binding to cerebellar and hippocampal neurons. Copine-5 was identified as the target antigen. Clinical manifestations included cognitive decline, confusion/disorientation, psychosis, seizures and signs and symptoms compatible with basal ganglia involvement (movement disorders, including secondary parkinsonism, and/or abulia/akinetic mutism), alongside pain (including painful tonic spasms and focal allodynia), dysarthria, dysphagia, and abducens nerve palsy. Brain magnetic resonance imaging disclosed hyperintense lesions in the basal ganglia and the temporal lobe. CSF analysis revealed mild pleocytosis, intrathecal IgG synthesis, and blood/CSF barrier dysfunction. Of particular note, all four patients had melanoma, with an occult primary in three. In one patient, melanoma diagnosis and immunotherapy with the anti-PD-1 immune checkpoint inhibitor nivolumab preceded the onset of AIE by 9 months. Glucocorticoid treatment and/or intravenous immunoglobulins led to transient improvement in at least three patients; however, all relapsed and three progressed to hypoactive delirium or mutism. Plasma exchange and cyclophosphamide treatment were followed by clinical improvement and stabilization in one patient, but potentially contributed to fatal infectious complications. Copine-5-IgG belonged to the strongly complement-activating IgG1 subclass and was produced intrathecally. Serum titers ranged between 1:1000 and 1:100,000. Conclusions: Copine-5 is a novel autoantibody target in AIE. Testing for anti-copine-5 autoantibodies should be included in the diagnostic workup of patients with AIE, especially, but not exclusively, if associated with melanoma or positive melanoma-associated tumor markers. Further studies investigating the immunopathogenesis of copine-5-related autoimmunity and the potential significance of anti-copine-5 as a novel paraneoplastic serological marker and of copine-5 as a histopathological tumor marker in patients with suspected melanoma are highly warranted.
- Open Access
- 2 July 2026
- Published by Wiley in Journal of Neurochemistry
- Vol. 170 (7) , e70512
Splice Type‐Specific Effects of Gαo Subunits on Cerebellar Anatomy and Synapse Formation
This study investigated the effect of single Gα o1 and Gα o2 , as well as double Gα o1/2 knockout on the cerebellar anatomy and synapse formation. The alpha subunit of the G protein Go exists in two splice variants. Knockout of certain Gαo subtypes result in strong—mainly motor—deficits in mice, and mutations in the responsible gene locus in humans can result in severe encephalopathies. We aimed to decipher the hitherto incompletely understood contribution of the individual Gα o subunits to the anatomy and synapse formation of the cerebellum. Knockout of Gα o1 reduced the size of the cerebellum by 11%, accompanied by maximal reductions of the molecular layer thickness in the central lobule III (−30%) and molecular layer area in the uvula (−33%). Knockout of Gα o2 increased cerebellar size, molecular layer thickness in central lobule II (+18.6%), and area of the culmen (+37%). Combined deletion of Gα o1 and Gα o2 reduced cerebellar size by 12%, molecular layer thickness and area of the declive (by −27.3% and −23.4%, respectively). Moreover, VGLUT2‐positive climbing fiber contacts to Purkinje cells were reduced in Gα o1 knockout mice (on average by 40%). Similarly, VGLUT1 expression was reduced (on average by 17.3%). The knockout of Gα o2 promoted climbing fiber contacts (+14.3% on average, at a maximum of +52.6% in the central lobule II), VGLUT1 was less affected. Double knockout mice exhibited negative effects on VGLUT2 (−35% overall number) and VGLUT1 (−23% on average in expression levels). VGAT‐positive synaptic contacts were also diminished for Gα o1 and double knockout (−25% and −31% overall number, respectively) and increased for Gα o2 knockout (+13% on average). In line with this, negative effects on the dendritic outgrowth of Purkinje cells were observed in both Gα o1 −/− and Gα o −/− mice, while knockout of Gα o2 promoted dendrite outgrowth. Taken together, the two Gαo splice variants contrarily contribute to the development of the cerebellum, with Gα o1 representing the dominant subunit. image
- 2 July 2026
- Published by Wiley in Journal of Neurochemistry
- Vol. 170 (7) , e70512
Open AccessSplice Type‐Specific Effects of Gαo Subunits on Cerebellar Anatomy and Synapse Formation
This study investigated the effect of single Gα o1 and Gα o2 , as well as double Gα o1/2 knockout on the cerebellar anatomy and synapse formation. The alpha subunit of the G protein Go exists in two splice variants. Knockout of certain Gαo subtypes result in strong—mainly motor—deficits in mice, and mutations in the responsible gene locus in humans can result in severe encephalopathies. We aimed to decipher the hitherto incompletely understood contribution of the individual Gα o subunits to the anatomy and synapse formation of the cerebellum. Knockout of Gα o1 reduced the size of the cerebellum by 11%, accompanied by maximal reductions of the molecular layer thickness in the central lobule III (−30%) and molecular layer area in the uvula (−33%). Knockout of Gα o2 increased cerebellar size, molecular layer thickness in central lobule II (+18.6%), and area of the culmen (+37%). Combined deletion of Gα o1 and Gα o2 reduced cerebellar size by 12%, molecular layer thickness and area of the declive (by −27.3% and −23.4%, respectively). Moreover, VGLUT2‐positive climbing fiber contacts to Purkinje cells were reduced in Gα o1 knockout mice (on average by 40%). Similarly, VGLUT1 expression was reduced (on average by 17.3%). The knockout of Gα o2 promoted climbing fiber contacts (+14.3% on average, at a maximum of +52.6% in the central lobule II), VGLUT1 was less affected. Double knockout mice exhibited negative effects on VGLUT2 (−35% overall number) and VGLUT1 (−23% on average in expression levels). VGAT‐positive synaptic contacts were also diminished for Gα o1 and double knockout (−25% and −31% overall number, respectively) and increased for Gα o2 knockout (+13% on average). In line with this, negative effects on the dendritic outgrowth of Purkinje cells were observed in both Gα o1 −/− and Gα o −/− mice, while knockout of Gα o2 promoted dendrite outgrowth. Taken together, the two Gαo splice variants contrarily contribute to the development of the cerebellum, with Gα o1 representing the dominant subunit. image
- Open Access
- 28 October 2024
- Published by Wiley in Journal of Neurochemistry
- Vol. 169 (2)
Gα o1 and Gα o1 /Gα o2 deletion differentially affect hippocampal mossy fiber tract anatomy and neuronal morphogenesis
The heterotrimeric G‐protein αo subunit is ubiquitously expressed in the CNS as two splice variants Gα o1 and Gα o2 , regulating various brain functions. Here, we investigated the effect of single Gα o1 , Gα o2 , and double Gα o1/2 knockout on the postnatal development of the murine mossy fiber tract, a central pathway of the hippocampal connectivity circuit. The size of the hippocampal synaptic termination fields covered by mossy fiber boutons together with various fiber length parameters of the tract was analyzed by immunohistochemical staining of the vesicular Zinc transporter 3 (ZnT3) or Synaptoporin at postnatal days 2, 4, 8, 12, 16, and in the adult. Ultimately, Gα o1 knockout resulted in a reduced developmental growth of synaptic mossy fiber terminal fields by 37% in the adult Stratum lucidum and by 30% in the total mossy fiber tract size. Other morphological parameters such as projection length of the infrapyramidal bundle of the tract were increased (+52% in Gα o1 −/− mice). In contrast, Gα o2 knockout had no effects on the mossy fiber tract. Moreover, by using primary heterozygous and homozygous Gα o1 knockout hippocampal cultures, we detected a strongly pronounced reduction in axon and dendrite length (−50% and −38%, respectively) as well as axon and dendrite arborization complexity (−75% and −72% branch nodes, respectively) in the homozygous knockout. Deletion of both splice variants Gα o1 and Gα o2 partially rescued the in vivo and completely reconstituted the in vitro effects, indicating an opposing functional relevance of the two Gα o splice variants for neuronal development and synaptic connectivity. image
- 28 October 2024
- Published by Wiley in Journal of Neurochemistry
- Vol. 169 (2)
Open AccessGα o1 and Gα o1 /Gα o2 deletion differentially affect hippocampal mossy fiber tract anatomy and neuronal morphogenesis
The heterotrimeric G‐protein αo subunit is ubiquitously expressed in the CNS as two splice variants Gα o1 and Gα o2 , regulating various brain functions. Here, we investigated the effect of single Gα o1 , Gα o2 , and double Gα o1/2 knockout on the postnatal development of the murine mossy fiber tract, a central pathway of the hippocampal connectivity circuit. The size of the hippocampal synaptic termination fields covered by mossy fiber boutons together with various fiber length parameters of the tract was analyzed by immunohistochemical staining of the vesicular Zinc transporter 3 (ZnT3) or Synaptoporin at postnatal days 2, 4, 8, 12, 16, and in the adult. Ultimately, Gα o1 knockout resulted in a reduced developmental growth of synaptic mossy fiber terminal fields by 37% in the adult Stratum lucidum and by 30% in the total mossy fiber tract size. Other morphological parameters such as projection length of the infrapyramidal bundle of the tract were increased (+52% in Gα o1 −/− mice). In contrast, Gα o2 knockout had no effects on the mossy fiber tract. Moreover, by using primary heterozygous and homozygous Gα o1 knockout hippocampal cultures, we detected a strongly pronounced reduction in axon and dendrite length (−50% and −38%, respectively) as well as axon and dendrite arborization complexity (−75% and −72% branch nodes, respectively) in the homozygous knockout. Deletion of both splice variants Gα o1 and Gα o2 partially rescued the in vivo and completely reconstituted the in vitro effects, indicating an opposing functional relevance of the two Gα o splice variants for neuronal development and synaptic connectivity. image
- Open Access
- 10 July 2024
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1412813
Brain-targeting autoantibodies in patients with dementia
Autoantibodies against proteins in the brain are increasingly considered as a potential cause of cognitive decline, not only in subacute autoimmune encephalopathies but also in slowly progressing impairment of memory in patients with classical neurodegenerative dementias. In this retrospective cohort study of 161 well-characterized patients with different forms of dementia and 34 controls, we determined the prevalence of immunoglobulin (Ig) G and IgA autoantibodies to brain proteins using unbiased immunofluorescence staining of unfixed murine brain sections. Autoantibodies were detected in 21.1% of dementia patients and in 2.9% of gender-matched controls, with higher frequencies in vascular dementia (42%), Alzheimer’s disease (30%), dementia of unknown cause (25%), and subjective cognitive impairment (16.7%). Underlying antigens involved glial fibrillary acidic protein (GFAP), glycine receptor, and Rho GTPase activating protein 26 (ARHGAP26), but also a range of yet undetermined epitopes on neurons, myelinated fiber tracts, choroid plexus, glial cells, and blood vessels. Antibody-positive patients were younger than antibody-negative patients but did not differ in the extent of cognitive impairment, epidemiological and clinical factors, or comorbidities. Further research is needed to understand the potential contribution to disease progression and symptomatology, and to determine the antigenic targets of dementia-associated autoantibodies.
- 10 July 2024
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1412813
Open AccessBrain-targeting autoantibodies in patients with dementia
Autoantibodies against proteins in the brain are increasingly considered as a potential cause of cognitive decline, not only in subacute autoimmune encephalopathies but also in slowly progressing impairment of memory in patients with classical neurodegenerative dementias. In this retrospective cohort study of 161 well-characterized patients with different forms of dementia and 34 controls, we determined the prevalence of immunoglobulin (Ig) G and IgA autoantibodies to brain proteins using unbiased immunofluorescence staining of unfixed murine brain sections. Autoantibodies were detected in 21.1% of dementia patients and in 2.9% of gender-matched controls, with higher frequencies in vascular dementia (42%), Alzheimer’s disease (30%), dementia of unknown cause (25%), and subjective cognitive impairment (16.7%). Underlying antigens involved glial fibrillary acidic protein (GFAP), glycine receptor, and Rho GTPase activating protein 26 (ARHGAP26), but also a range of yet undetermined epitopes on neurons, myelinated fiber tracts, choroid plexus, glial cells, and blood vessels. Antibody-positive patients were younger than antibody-negative patients but did not differ in the extent of cognitive impairment, epidemiological and clinical factors, or comorbidities. Further research is needed to understand the potential contribution to disease progression and symptomatology, and to determine the antigenic targets of dementia-associated autoantibodies.
- Open Access
- 30 January 2023
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 17, 1077204
Brain blood vessel autoantibodies in patients with NMDA and GABAA receptor encephalitis: identification of unconventional Myosin-X as target antigen
Introduction: The antibody repertoire from CSF-derived antibody-secreting cells and memory B-cells in patients with encephalitis contains a considerable number of antibodies that do not target the disease-defining autoantigen such as the GABA or NMDA receptors. This study focuses on the functional relevance of autoantibodies to brain blood vessels in patients with GABAA and NMDA receptor encephalitis.Methods: We tested 149 human monoclonal IgG antibodies from the cerebrospinal fluid of six patients with different forms of autoimmune encephalitis on murine brain sections for reactivity to blood vessels using immunohistochemistry. Positive candidates were tested for reactivity with purified brain blood vessels, effects on transendothelial electrical resistance (TEER), and expression of tight junction proteins as well as gene regulation using human brain microvascular endothelial hCMEC/D3 cells as in vitro blood-brain barrier model. One blood-vessel reactive antibody was infused intrathecally by pump injection in mice to study in vivo binding and effects on tight junction proteins such as Occludin. Target protein identification was addressed using transfected HEK293 cells.Results: Six antibodies reacted with brain blood vessels, three were from the same patient with GABAAR encephalitis, and the other three were from different patients with NMDAR encephalitis. One antibody from an NMDAR encephalitis patient, mAb 011-138, also reacted with cerebellar Purkinje cells. In this case, treatment of hCMEC/D3 cells resulted in decreased TEER, reduced Occludin expression, and mRNA levels. Functional relevance in vivo was confirmed as Occludin downregulation was observed in mAb 011-138-infused animals. Unconventional Myosin-X was identified as a novel autoimmune target for this antibody.Discussion: We conclude that autoantibodies to blood vessels occur in autoimmune encephalitis patients and might contribute to a disruption of the blood-brain barrier thereby suggesting a potential pathophysiological relevance of these antibodies.
- 30 January 2023
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 17, 1077204
Open AccessBrain blood vessel autoantibodies in patients with NMDA and GABAA receptor encephalitis: identification of unconventional Myosin-X as target antigen
Introduction: The antibody repertoire from CSF-derived antibody-secreting cells and memory B-cells in patients with encephalitis contains a considerable number of antibodies that do not target the disease-defining autoantigen such as the GABA or NMDA receptors. This study focuses on the functional relevance of autoantibodies to brain blood vessels in patients with GABAA and NMDA receptor encephalitis.Methods: We tested 149 human monoclonal IgG antibodies from the cerebrospinal fluid of six patients with different forms of autoimmune encephalitis on murine brain sections for reactivity to blood vessels using immunohistochemistry. Positive candidates were tested for reactivity with purified brain blood vessels, effects on transendothelial electrical resistance (TEER), and expression of tight junction proteins as well as gene regulation using human brain microvascular endothelial hCMEC/D3 cells as in vitro blood-brain barrier model. One blood-vessel reactive antibody was infused intrathecally by pump injection in mice to study in vivo binding and effects on tight junction proteins such as Occludin. Target protein identification was addressed using transfected HEK293 cells.Results: Six antibodies reacted with brain blood vessels, three were from the same patient with GABAAR encephalitis, and the other three were from different patients with NMDAR encephalitis. One antibody from an NMDAR encephalitis patient, mAb 011-138, also reacted with cerebellar Purkinje cells. In this case, treatment of hCMEC/D3 cells resulted in decreased TEER, reduced Occludin expression, and mRNA levels. Functional relevance in vivo was confirmed as Occludin downregulation was observed in mAb 011-138-infused animals. Unconventional Myosin-X was identified as a novel autoimmune target for this antibody.Discussion: We conclude that autoantibodies to blood vessels occur in autoimmune encephalitis patients and might contribute to a disruption of the blood-brain barrier thereby suggesting a potential pathophysiological relevance of these antibodies.
- Open Access
- 15 June 2022
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 16, 860823
Enhancement of Phosphorylation and Transport Activity of the Neuronal Glutamate Transporter Excitatory Amino Acid Transporter 3 by C3bot and a 26mer C3bot Peptide
In primary murine hippocampal neurons we investigated the regulation of EAAT3-mediated glutamate transport by the Clostridium botulinum C3 transferase C3bot and a 26mer peptide derived from full length protein. Incubation with either enzyme-competent C3bot or enzyme-deficient C3bot156–181 peptide resulted in the upregulation of glutamate uptake by up to 22% compared to untreated cells. A similar enhancement of glutamate transport was also achieved by the classical phorbol-ester-mediated activation of protein kinase C subtypes. Yet comparable, effects elicited by C3 preparations seemed not to rely on PKCα, γ, ε, or ζ activation. Blocking of tyrosine phosphorylation by tyrosine kinase inhibitors prevented the observed effect mediated by C3bot and C3bot 26mer. By using biochemical and molecular biological assays we could rule out that the observed C3bot and C3bot 26mer-mediated effects solely resulted from enhanced transporter expression or translocation to the neuronal surface but was rather mediated by transporter phosphorylation at tyrosine residues that was found to be significantly enhanced following incubation with either full length protein or the 26mer C3 peptide.
- 15 June 2022
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 16, 860823
Open AccessEnhancement of Phosphorylation and Transport Activity of the Neuronal Glutamate Transporter Excitatory Amino Acid Transporter 3 by C3bot and a 26mer C3bot Peptide
In primary murine hippocampal neurons we investigated the regulation of EAAT3-mediated glutamate transport by the Clostridium botulinum C3 transferase C3bot and a 26mer peptide derived from full length protein. Incubation with either enzyme-competent C3bot or enzyme-deficient C3bot156–181 peptide resulted in the upregulation of glutamate uptake by up to 22% compared to untreated cells. A similar enhancement of glutamate transport was also achieved by the classical phorbol-ester-mediated activation of protein kinase C subtypes. Yet comparable, effects elicited by C3 preparations seemed not to rely on PKCα, γ, ε, or ζ activation. Blocking of tyrosine phosphorylation by tyrosine kinase inhibitors prevented the observed effect mediated by C3bot and C3bot 26mer. By using biochemical and molecular biological assays we could rule out that the observed C3bot and C3bot 26mer-mediated effects solely resulted from enhanced transporter expression or translocation to the neuronal surface but was rather mediated by transporter phosphorylation at tyrosine residues that was found to be significantly enhanced following incubation with either full length protein or the 26mer C3 peptide.
- Open Access
- 3 November 2020
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 14
The Higher Sensitivity of GABAergic Compared to Glutamatergic Neurons to Growth-Promoting C3bot Treatment Is Mediated by Vimentin
The current study investigates the neurotrophic effects of Clostridium botulinum C3 transferase (C3bot) on highly purified, glia-free, GABAergic, and glutamatergic neurons. Incubation with nanomolar concentrations of C3bot promotes dendrite formation as well as dendritic and axonal outgrowth in rat GABAergic neurons. A comparison of C3bot effects on sorted mouse GABAergic and glutamatergic neurons obtained from newly established NexCre;Ai9xVGAT Venus mice revealed a higher sensitivity of GABAergic cells to axonotrophic and dendritic effects of C3bot in terms of process length and branch formation. Protein biochemical analysis of known C3bot binding partners revealed comparable amounts of β1 integrin in both cell types but a higher expression of vimentin in GABAergic neurons. Accordingly, binding of C3bot to GABAergic neurons was stronger than binding to glutamatergic neurons. A combinatory treatment of glutamatergic neurons with C3bot and vimentin raised the amount of bound C3bot to levels comparable to the ones in GABAergic neurons, thereby confirming the specificity of effects. Overall, different surface vimentin levels between GABAergic and glutamatergic neurons exist that mediate neurotrophic C3bot effects.
- 3 November 2020
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 14
Open AccessThe Higher Sensitivity of GABAergic Compared to Glutamatergic Neurons to Growth-Promoting C3bot Treatment Is Mediated by Vimentin
The current study investigates the neurotrophic effects of Clostridium botulinum C3 transferase (C3bot) on highly purified, glia-free, GABAergic, and glutamatergic neurons. Incubation with nanomolar concentrations of C3bot promotes dendrite formation as well as dendritic and axonal outgrowth in rat GABAergic neurons. A comparison of C3bot effects on sorted mouse GABAergic and glutamatergic neurons obtained from newly established NexCre;Ai9xVGAT Venus mice revealed a higher sensitivity of GABAergic cells to axonotrophic and dendritic effects of C3bot in terms of process length and branch formation. Protein biochemical analysis of known C3bot binding partners revealed comparable amounts of β1 integrin in both cell types but a higher expression of vimentin in GABAergic neurons. Accordingly, binding of C3bot to GABAergic neurons was stronger than binding to glutamatergic neurons. A combinatory treatment of glutamatergic neurons with C3bot and vimentin raised the amount of bound C3bot to levels comparable to the ones in GABAergic neurons, thereby confirming the specificity of effects. Overall, different surface vimentin levels between GABAergic and glutamatergic neurons exist that mediate neurotrophic C3bot effects.
- Open Access
- 16 August 2020
- Published by Cold Spring Harbor Laboratory in bioRxiv
A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model
The emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019 (COVID-19), manifesting with respiratory symptoms and multi-organ dysfunction. Detailed characterization of virus-neutralizing antibodies and target epitopes is needed to understand COVID-19 pathophysiology and guide immunization strategies. Among 598 human monoclonal antibodies (mAbs) from ten COVID-19 patients, we identified 40 strongly neutralizing mAbs. The most potent mAb CV07-209 neutralized authentic SARS-CoV-2 with IC50of 3.1 ng/ml. Crystal structures of two mAbs in complex with the SARS-CoV-2 receptor-binding domain at 2.55 and 2.70 Å revealed a direct block of ACE2 attachment. Interestingly, some of the near-germline SARS-CoV-2 neutralizing mAbs reacted with mammalian self-antigens. Prophylactic and therapeutic application of CV07-209 protected hamsters from SARS-CoV-2 infection, weight loss and lung pathology. Our results show that non-self-reactive virus-neutralizing mAbs elicited during SARS-CoV-2 infection are a promising therapeutic strategy.
- 16 August 2020
- Published by Cold Spring Harbor Laboratory in bioRxiv
Open AccessA SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model
The emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019 (COVID-19), manifesting with respiratory symptoms and multi-organ dysfunction. Detailed characterization of virus-neutralizing antibodies and target epitopes is needed to understand COVID-19 pathophysiology and guide immunization strategies. Among 598 human monoclonal antibodies (mAbs) from ten COVID-19 patients, we identified 40 strongly neutralizing mAbs. The most potent mAb CV07-209 neutralized authentic SARS-CoV-2 with IC50of 3.1 ng/ml. Crystal structures of two mAbs in complex with the SARS-CoV-2 receptor-binding domain at 2.55 and 2.70 Å revealed a direct block of ACE2 attachment. Interestingly, some of the near-germline SARS-CoV-2 neutralizing mAbs reacted with mammalian self-antigens. Prophylactic and therapeutic application of CV07-209 protected hamsters from SARS-CoV-2 infection, weight loss and lung pathology. Our results show that non-self-reactive virus-neutralizing mAbs elicited during SARS-CoV-2 infection are a promising therapeutic strategy.
- 10 February 2020
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 237 (02) , 128-132
Neuroprotektion und Regeneration im Zentralnervensystem
Zusammenfassung: Die Entwicklung neuroprotektiver und regenerativer Therapieansätze im Zentralnervensystem (ZNS) stellt eine große Herausforderung in der klinischen und grundlagenbasierten Forschung dar. Im Gegensatz zum peripheren Nervensystem, das eine vergleichsweise hohe intrinsische Regenerationsfähigkeit zeigt, ist diese Eigenschaft im adulten ZNS nur schwach ausgeprägt. In dieser Übersichtsarbeit sollen einige grundlegende Wachstumsmechanismen zentralnervöser Neurone beleuchtet werden, ebenso wie Faktoren, die einer erfolgreichen Regeneration nach Schädigung entgegenstehen. Vorwiegend im Kontext der Glaukomerkrankung werden präklinische und klinische Studien vorgestellt, die das Verständnis neurodegenerativer Vorgänge im optischen System verbessern und somit die Grundlagen für aktuelle und zukünftige Therapiestrategien liefern können.
- 10 February 2020
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 237 (02) , 128-132
Neuroprotektion und Regeneration im Zentralnervensystem
Zusammenfassung: Die Entwicklung neuroprotektiver und regenerativer Therapieansätze im Zentralnervensystem (ZNS) stellt eine große Herausforderung in der klinischen und grundlagenbasierten Forschung dar. Im Gegensatz zum peripheren Nervensystem, das eine vergleichsweise hohe intrinsische Regenerationsfähigkeit zeigt, ist diese Eigenschaft im adulten ZNS nur schwach ausgeprägt. In dieser Übersichtsarbeit sollen einige grundlegende Wachstumsmechanismen zentralnervöser Neurone beleuchtet werden, ebenso wie Faktoren, die einer erfolgreichen Regeneration nach Schädigung entgegenstehen. Vorwiegend im Kontext der Glaukomerkrankung werden präklinische und klinische Studien vorgestellt, die das Verständnis neurodegenerativer Vorgänge im optischen System verbessern und somit die Grundlagen für aktuelle und zukünftige Therapiestrategien liefern können.
- Open Access
- 13 December 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (12) , e0208636
Epitope specificity of anti-synapsin autoantibodies: Differential targeting of synapsin I domains
To identify the specific domains of the presynaptic protein synapsin targeted by recently described autoantibodies to synapsin. Sera of 20 and CSF of two patients with different psychiatric and neurological disorders previously tested positive for immunoglobulin (Ig)G antibodies to full-length synapsin were screened for IgG against synapsin I domains using HEK293 cells transfected with constructs encoding different domains of rat synapsin Ia. Additionally, IgG subclasses were determined using full-length synapsin Ia. Serum and CSF from one patient were also screened for IgA autoantibodies to synapsin I domains. Sera from nine and CSF from two healthy subjects were analyzed as controls. IgG in serum from 12 of 20 IgG synapsin full-length positive patients, but from none of the healthy controls, bound to synapsin domains. Of these 12 sera, six bound to the A domain, five to the D domain, and one to the B- (and possibly A-), D-, and E-domains of synapsin I. IgG antibodies to the D-domain were also detected in one of the CSF samples. Determination of IgG subclasses detected IgG1 in two sera and one CSF, IgG2 in none of the samples, IgG3 in two sera, and IgG4 in eight sera. One patient known to be positive for IgA antibodies to full-length synapsin had IgA antibodies to the D-domain in serum and CSF. Anti-synapsin autoantibodies preferentially bind to either the A- or the D-domain of synapsin I.
- 13 December 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (12) , e0208636
Open AccessEpitope specificity of anti-synapsin autoantibodies: Differential targeting of synapsin I domains
To identify the specific domains of the presynaptic protein synapsin targeted by recently described autoantibodies to synapsin. Sera of 20 and CSF of two patients with different psychiatric and neurological disorders previously tested positive for immunoglobulin (Ig)G antibodies to full-length synapsin were screened for IgG against synapsin I domains using HEK293 cells transfected with constructs encoding different domains of rat synapsin Ia. Additionally, IgG subclasses were determined using full-length synapsin Ia. Serum and CSF from one patient were also screened for IgA autoantibodies to synapsin I domains. Sera from nine and CSF from two healthy subjects were analyzed as controls. IgG in serum from 12 of 20 IgG synapsin full-length positive patients, but from none of the healthy controls, bound to synapsin domains. Of these 12 sera, six bound to the A domain, five to the D domain, and one to the B- (and possibly A-), D-, and E-domains of synapsin I. IgG antibodies to the D-domain were also detected in one of the CSF samples. Determination of IgG subclasses detected IgG1 in two sera and one CSF, IgG2 in none of the samples, IgG3 in two sera, and IgG4 in eight sera. One patient known to be positive for IgA antibodies to full-length synapsin had IgA antibodies to the D-domain in serum and CSF. Anti-synapsin autoantibodies preferentially bind to either the A- or the D-domain of synapsin I.